APTUS PHARMA IPO
Dhan Kirti is pleased to present a comprehensive overview of the upcoming APTUS PHARMA IPO, offering investors valuable insights into the company, its financial details, and the potential investment opportunity. This initial public offering provides a chance to understand a pharmaceutical company focused on an asset-light marketing and distribution model.
Snapshot of the Offering
| IPO Period | 23rd – 25th Sep 2025 |
|---|---|
| Listing on | 30 Sep 2025 |
| Price Band | ₹65 – ₹70 |
| Lot Size & Minimum Investment | 2000 shares — ₹140000 |
| Total Issue Size | ₹13.02 crores |
The APTUS PHARMA IPO is entirely a fresh issue, indicating that all proceeds will directly flow into the company to fuel its growth and strategic initiatives. Investors should mark their calendars for these crucial dates to ensure timely participation.
Key Dates for Potential Investors
- Opening Date: 23 Sep 2025
- Closing Date: 25 Sep 2025
- UPI Payment Deadline: 25 Sep 2025 (5 PM)
- Allotment Announcement: 26 Sep 2025
- Refund Processing: 29 Sep 2025
- Demat Credit: 29 Sep 2025
- Stock Market Listing: 30 Sep 2025
- Mandate Validity End: 10 Oct 2025
- Anchor Investor Lock-in Release (50%): 26 Oct 2025
- Anchor Investor Lock-in Release (Remaining): 25 Dec 2025
*Dates may be revised as per official updates and regulatory requirements. It is advisable to refer to the official public notices for any last-minute changes.
Company Overview: Aptus Pharma’s Business Model
Aptus Pharma, incorporated in 2010 and based in Gujarat, specializes in the marketing and distribution of finished pharmaceutical formulations. The company utilizes an asset-light model, partnering with seven contract manufacturing units instead of owning its facilities. This strategic approach enables Aptus Pharma to concentrate on market penetration, product development, and building robust distribution networks.
Its diverse product portfolio covers key therapeutic areas such as anti-infectives, gastrointestinal, antacids, anti-allergic, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, anti-diabetic, and wellness products. These are offered in various dosage forms, including tablets, capsules, syrups, injections, ointments, and drops, broadening its market appeal and catering to diverse patient needs within the dynamic Indian pharmaceutical market.
IPO Funding Structure and Capital Infusion
| Total Funds Raised | ₹13.02 crores |
|---|---|
| Fresh Issue Component | ₹13.02 crores |
| Offer for Sale Component | Nil |
The entire issue size of ₹13.02 crores constitutes a fresh issue. This structure means that all the capital raised through this IPO will directly infuse into Aptus Pharma, providing a significant boost to its operational capabilities and growth initiatives. The absence of an Offer for Sale (OFS) component indicates that the primary objective is to raise capital for company expansion rather than providing an exit for existing shareholders.
Strategic Utilization of IPO Proceeds
Aptus Pharma plans to strategically deploy the funds raised from the IPO to bolster its operational growth and expansion. This allocation reflects the company’s commitment to sustainable development:
| Objective | Amount (INR Crores) | Allocation % |
|---|---|---|
| Capital expenditure | 1.63 | 12.5% |
| Working capital requirements | 8.00 | 61.5% |
| General Corporate Purposes and miscellaneous | 3.39 | 26% |
A substantial 61.5% of the proceeds is allocated to working capital, which is essential for managing daily operations, including procurement, inventory management, and efficient distribution logistics. Approximately 12.5% is designated for capital expenditure, likely aimed at enhancing operational infrastructure such as IT systems or logistics capabilities to support its expanding network. The remaining 26% is set aside for general corporate purposes, providing crucial flexibility for strategic initiatives, unforeseen exigencies, and overall business development, enabling the company to adapt and pursue new opportunities.
Core Strengths Driving Aptus Pharma’s Growth Trajectory
Aptus Pharma possesses several inherent strengths that contribute to its market standing and future potential:
- Established Market Footprint: Since its incorporation in 2010, Aptus Pharma has built a strong market presence in pharmaceutical marketing and distribution. This experience has fostered key relationships with medical professionals and a recognizable brand within the industry.
- Expansive Product Portfolio: The company offers a broad array of pharmaceutical products across numerous therapeutic categories and dosage forms. This diversification mitigates reliance on any single product segment, enhancing revenue stability and market reach.
- Flexible Manufacturing Partnerships: Operating through an asset-light contract manufacturing model with seven established units provides significant operational flexibility. This approach reduces capital expenditure and allows for scalability based on market demand.
- Experienced Leadership Team: The promoter group brings considerable expertise and deep understanding of the pharmaceutical industry. Their extensive experience is crucial in navigating regulatory complexities, identifying market trends, and guiding the company’s growth effectively.
Key Considerations and Potential Investment Risks
While Aptus Pharma presents compelling strengths, potential investors should also be aware of certain risk factors inherent in its business model:
- Reliance on Contract Manufacturers: Complete dependence on third-party contract manufacturers exposes the company to supply chain vulnerabilities. Any disruption, quality control issue, or changes in terms with these partners could impact product availability, quality, and financial performance.
- Limited Control Over Production: Without owning manufacturing facilities, Aptus Pharma has limited direct control over the production process, quality assurance, and cost efficiencies. This reliance necessitates strict monitoring of partners’ adherence to standards.
- Complex Regulatory Compliance: Operating across multiple therapeutic categories and formulations exposes Aptus Pharma to a complex and ever-evolving regulatory environment. Non-compliance in any segment could lead to product recalls, penalties, legal issues, and significant financial and reputational damage.
- Dependence on Key Partners: A significant portion of the company’s business continuity and product quality relies on the performance and stability of its key manufacturing partners. The loss of a major partner could severely disrupt Aptus Pharma’s ability to supply products and meet market demand.
Updated IPO Subscription Performance
As of the IPO’s closing on September 25, 2025, at 5:00 PM, the subscription data reflects significant investor interest across all categories:
| Investor Category | Shares Reserved (Lakhs) | Shares Applied (Lakhs) | Subscription (Times) |
|---|---|---|---|
| Qualified Institutional Buyers (QIB) | 3.52 | 4.36 | 1.24 |
| Non-Institutional Investors (NII) | 2.66 | 76.48 | 28.75 |
| Retail Individual Investors (RII) | 6.20 | 194.88 | 31.43 |
| Total | 12.38 | 275.72 | 22.27 |
*The subscription data reflects the interest shown by various investor categories. The grey market premium (GMP) figures are unofficial and highly speculative, thus they are not considered reliable indicators for investment decisions. Exchange-published data and company fundamentals are more robust metrics for evaluation.
Participate in This Opportunity
Investors interested in participating in the APTUS PHARMA IPO can do so through the official Dhan Kirti IPO platform. Ensure your application is submitted before the subscription window closes on September 25, 2025, to be considered for allotment.
For more details and to apply for the IPO, visit the Dhan Kirti IPO platform.
Disclaimer: Investing in IPOs carries risks. Please read the Red Herring Prospectus (RHP) carefully before making any investment decisions. This content is for informational purposes only and does not constitute investment advice.
